BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28774214)

  • 1. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
    Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
    Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V; Wang A; Prescott H
    Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosutinib - related pleural effusion in patients with chronic myeloid leukemia.
    Yüzbaşıoğlu MB; Eşkazan AE
    Expert Opin Drug Saf; 2021 Apr; 20(4):379-381. PubMed ID: 33339467
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
    Caocci G; Mulas O; Abruzzese E; Iurlo A; Annunziata M; Orlandi EM; Galimberti S; Binotto G; Sgherza N; Luciano L; Martino B; Russo Rossi A; Bonifacio M; Fozza C; Trawinska MM; Cattaneo D; Elena C; Baratè C; De Gregorio F; Molica M; La Nasa G; Foà R; Breccia M
    Ann Hematol; 2019 Aug; 98(8):1885-1890. PubMed ID: 31044260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.
    Cortes JE; Apperley JF; DeAngelo DJ; Deininger MW; Kota VK; Rousselot P; Gambacorti-Passerini C
    J Hematol Oncol; 2018 Dec; 11(1):143. PubMed ID: 30587215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
    Keller-V Amsberg G; Brümmendorf TH
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1121-7. PubMed ID: 23098112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
    Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
    Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
    Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
    Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
    García-Gutiérrez V; Milojkovic D; Hernandez-Boluda JC; Claudiani S; Martin Mateos ML; Casado-Montero LF; González G; Jimenez-Velasco A; Boque C; Martinez-Trillos A; Vázquez IM; Payer ÁR; Senín A; Amustio Díez E; García AB; Carrascosa GB; Ortí G; Ruiz BC; Fernández MÁ; Del Carmen García Garay M; Giraldo P; Guinea JM; De Las Heras Rodríguez N; Hernán N; Pérez AI; Piris-Villaespesa M; Lorenzo JLL; Martí-Tutusaus JMM; Vallansot RO; Ortega Rivas F; Puerta JM; Ramirez MJ; Romero E; Romo A; Rosell A; Saavedra SS; Sebrango A; Tallon J; Valencia S; Portero A; Steegmann JL;
    Ann Hematol; 2019 Feb; 98(2):321-330. PubMed ID: 30446802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to treat chronic myeloid leukemia (CML) in older adults.
    Luskin MR; DeAngelo DJ
    J Geriatr Oncol; 2018 Jul; 9(4):291-295. PubMed ID: 29463446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.
    Valent P; Herndlhofer S; Schneeweiß M; Boidol B; Ringler A; Kubicek S; Gleixner KV; Hoermann G; Hadzijusufovic E; Müllauer L; Sperr WR; Superti-Furga G; Mannhalter C
    Oncotarget; 2017 Apr; 8(14):23061-23072. PubMed ID: 28416739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
    Gambacorti-Passerini C; Cortes JE; Lipton JH; Dmoszynska A; Wong RS; Rossiev V; Pavlov D; Gogat Marchant K; Duvillié L; Khattry N; Kantarjian HM; Brümmendorf TH
    Am J Hematol; 2014 Oct; 89(10):947-53. PubMed ID: 24944159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
    Gambacorti-Passerini C; Kantarjian HM; Kim DW; Khoury HJ; Turkina AG; Brümmendorf TH; Matczak E; Bardy-Bouxin N; Shapiro M; Turnbull K; Leip E; Cortes JE
    Am J Hematol; 2015 Sep; 90(9):755-68. PubMed ID: 26040495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
    Hill BG; Kota VK; Khoury HJ
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.
    Takahashi N; Nakaseko C; Kobayashi Y; Miyamura K; Ono C; Koide Y; Fujii Y; Ohnishi K
    Int J Hematol; 2017 Sep; 106(3):398-410. PubMed ID: 28409328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.
    Khoury HJ; Gambacorti-Passerini C; Brümmendorf TH
    Ann Oncol; 2018 Mar; 29(3):578-587. PubMed ID: 29385394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
    Keller G; Schafhausen P; Brummendorf TH
    Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
    Cortes JE; Gambacorti-Passerini C; Kim DW; Kantarjian HM; Lipton JH; Lahoti A; Talpaz M; Matczak E; Barry E; Leip E; Brümmendorf TH; Khoury HJ
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):684-695.e6. PubMed ID: 28807791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.